

Synonyms

LY6K

Source

Cynomolgus LY6K Protein, Fc Tag (LYK-C5253) is expressed from human 293 cells (HEK293). It contains AA His 18 - Gly 138 (Accession # [A0A7N9CPV3](#)).

Predicted N-terminus: His 18

Molecular Characterization

LY6K(His 18 - Gly 138) A0A7N9CPV3	Fc(Pro 100 - Lys 330) P01857-1
--------------------------------------	-----------------------------------

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 40.5 kDa. The protein migrates as 43-55 kDa when calibrated against [Star Ribbon Pre-stained Protein Marker](#) under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per µg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.


This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)

SDS-PAGE



Cynomolgus LY6K Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With [Star Ribbon Pre-stained Protein Marker](#)).

Background

Lymphocyte antigen 6K (LY6K) is a small GPI-linked protein that is normally expressed in testes. Increased expression of LY6K is significantly associated with poor survival outcomes in many solid cancers, including cancers of the breast, ovary, gastrointestinal tract, head and neck, brain, bladder, and lung.



www.acrobiosystems.com